XT
ZVSA

XTX Topco’s ZyVersa Therapeutics ZVSA Stock Holding History

XTX Topco’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-48
Closed -$2.19K – 2238
2023
Q3 		$2.19K Buy
+48
New +$2.85K ﹤0.01% 1494

Other funds holding ZVSA

AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

XTX Topco's ZVSA Position: Q4 2023 in Review

XTX Topco sold out of ZyVersa Therapeutics (ZVSA) in Q4 2023, closing a stake of 48 shares — an estimated $2.19K sold.

XTX Topco first reported a position in ZVSA in Q3 2023 and held it in 1 quarter. The position peaked at $2.19K in Q3 2023. 6 funds tracked by Wall St. Rank hold ZVSA as of Q4 2023.

  • XTX Topco reported no remaining ZyVersa Therapeutics position as of Q4 2023 after selling out during the quarter.
  • XTX Topco sold 48 ZyVersa Therapeutics shares in Q4 2023, an estimated $2.19K.
  • XTX Topco first reported a position in ZyVersa Therapeutics in Q3 2023 and held it in 1 quarter.
  • XTX Topco's ZyVersa Therapeutics position peaked at $2.19K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2023.

Based on XTX Topco's 13F filing for Q4 2023, filed 13 Feb 2024.